Advertisement

Endocrine and Metabolic Consequences of Turner Syndrome

  • Mette H. Viuff
  • Claus H. GravholtEmail author
Chapter
  • 21 Downloads

Abstract

Numerous important advances have been noted during recent years. These advances cover all specialty fields involved in the care of girls and women with TS, including (1) diagnostic and genetic issues, (2) growth and development during childhood and adolescence, (3) congenital and acquired cardiovascular disease, (4) transition and adult care, and (5) other comorbidities and neurocognitive issues. Here, we will present the most important new advances concerning endocrine and metabolic care of Turner syndrome.

Osteoporosis, diabetes, both type 1 and 2, hypothyroidism, obesity, and a host of other endocrinological diseases and conditions are seen more frequently in Turner syndrome in the long term. Other autoimmune diseases, such as celiac disease and inflammatory bowel disease, are seen with quite increased frequency. Prevention, intervention, and proper treatment is only just being recognized.

Morbidity and mortality is quite elevated and many conditions need to be vigorously and routinely checked for and diagnosed as early as possible in order to prevent long-term health consequences. Endocrine and metabolic disease contributes significantly to morbidity and is contributing to the reduced life span of women with TS and much of this morbidity can be prevented.

Keywords

Autoimmune disease Type 1 diabetes Type 2 diabetes Celiac disease Inflammatory bowel disease Hormone replacement therapy Obesity Metabolic syndrome Osteoporosis Rheumatoid arthritis 

References

  1. 1.
    Stochholm K, Juul S, Juel K, Naeraa RW, Gravholt CH. Prevalence, incidence, diagnostic delay, and mortality in Turner syndrome. J Clin Endocrinol Metab. 2006;91(10):3897–902.PubMedCrossRefGoogle Scholar
  2. 2.
    Gravholt CH, Juul S, Naeraa RW, Hansen J. Morbidity in Turner syndrome. J Clin Epidemiol. 1998;51(2):147–58.PubMedCrossRefGoogle Scholar
  3. 3.
    Elsheikh M, Wass JA, Conway GS. Autoimmune thyroid syndrome in women with Turner’s syndrome–the association with karyotype. Clin Endocrinol. 2001;55(2):223–6.CrossRefGoogle Scholar
  4. 4.
    El-Mansoury M, Bryman I, Berntorp K, Hanson C, Wilhelmsen L, Landin-Wilhelmsen K. Hypothyroidism is common in Turner syndrome: results of a five-year follow-up. J Clin Endocrinol Metab. 2005;90(4):2131–5.PubMedCrossRefGoogle Scholar
  5. 5.
    Wilson R, Chu CE, Donaldson MD, Thomson JA, McKillop JH, Connor JM. An increased incidence of thyroid antibodies in patients with Turner’s syndrome and their first degree relatives. Autoimmunity. 1996;25(1):47–52.PubMedCrossRefGoogle Scholar
  6. 6.
    Pai GS, Leach DC, Weiss L, Wolf C, Van Dyke DL. Thyroid abnormalities in 20 children with Turner syndrome. J Pediatr. 1977;91(2):267–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Bakalov VK, Gutin L, Cheng CM, et al. Autoimmune disorders in women with Turner syndrome and women with karyotypically normal primary ovarian insufficiency. J Autoimmun. 2013;38(4):315–21.CrossRefGoogle Scholar
  8. 8.
    Mortensen KH, Cleemann L, Hjerrild BE, et al. Increased prevalence of autoimmunity in Turner syndrome – influence of age. Clin Exp Immunol. 2009;156(2):205–10.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Poppe K, Velkeniers B. Thyroid disorders in infertile women. Ann Endocrinol (Paris). 2003;64(1):45–50.Google Scholar
  10. 10.
    Invernizzi P, Miozzo M, Selmi C, et al. X chromosome monosomy: a common mechanism for autoimmune diseases. J Immunol. 2005;175(1):575–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Invernizzi P, Miozzo M, Oertelt-Prigione S, et al. X monosomy in female systemic lupus erythematosus. Ann N Y Acad Sci. 2007;1110:84–91.PubMedCrossRefGoogle Scholar
  12. 12.
    Libert C, Dejager L, Pinheiro I. The X chromosome in immune functions: when a chromosome makes the difference. Nat Rev Immunol. 2010;10(8):594–604.PubMedCrossRefGoogle Scholar
  13. 13.
    Højbjerg Gravholt C, Christian Klausen I, Weeke J, Sandahl Christiansen J. Lp(a) and lipids in adult Turner’s syndrome: impact of treatment with 17beta-estradiol and norethisterone. Atherosclerosis. 2000;150(1):201–8.CrossRefGoogle Scholar
  14. 14.
    Lowenstein EJ, Kim KH, Glick SA. Turner’s syndrome in dermatology. J Am Acad Dermatol. 2004;50(5):767–76.PubMedCrossRefGoogle Scholar
  15. 15.
    Hayward PA, Satsangi J, Jewell DP. Inflammatory bowel disease and the X chromosome. QJM. 1996;89(9):713–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Wihlborg CE, Babyn PS, Schneider R, Canada MG. The association between Turner’s syndrome and juvenile rheumatoid arthritis. Pediatr Radiol. 1999;29(9):676–81.PubMedCrossRefGoogle Scholar
  17. 17.
    Grossi A, Crinò A, Luciano R, Lombardo A, Cappa M, Fierabracci A. Endocrine autoimmunity in Turner syndrome. Ital J Pediatr. 2013;39:79.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Jørgensen KT, Rostgaard K, Bache I, et al. Autoimmune diseases in women with Turner’s syndrome. Arthritis Rheum. 2010;62(3):658–66.PubMedCrossRefGoogle Scholar
  19. 19.
    Germain EL, Plotnick LP. Age-related anti-thyroid antibodies and thyroid abnormalities in Turner syndrome. Acta Paediatr Scand. 1986;75(5):750–5.PubMedCrossRefGoogle Scholar
  20. 20.
    Goldacre MJ, Seminog OO. Turner syndrome and autoimmune diseases: record-linkage study. Arch Dis Child. 2014;99(1):71–3.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Price WH. A high incidence of chronic inflammatory bowel disease in patients with Turner’s syndrome. J Med Genet. 1979;16(4):263–6.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Kohler J, Grant D. Crohn’s disease in Turner’s syndrome. Br Med J. 1981;282:950.CrossRefGoogle Scholar
  23. 23.
    Arslan D, Kuyucu T, Kendirci M, Kurtoglu S. Celiac disease and Turner’s syndrome: patient report. J Pediatr Endocrinol Metab. 2000;13(9):1629–31.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Rujner J, Wisniewski A, Gregorek H, Wozniewicz B, Młynarski W, Witas HW. Coeliac disease and HLA-DQ 2 (DQA1∗ 0501 and DQB1∗ 0201) in patients with Turner syndrome. J Pediatr Gastroenterol Nutr. 2001;32(1):114–5.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Mårild K, Størdal K, Hagman A, Ludvigsson JF. Turner syndrome and celiac disease: a case-control study. Pediatrics. 2016;137(2):1–8.CrossRefGoogle Scholar
  26. 26.
    Scarpa R, Lubrano E, Castiglione F, Morace F, Ames PR, Oriente P. Juvenile rheumatoid arthritis, Crohn’s disease and Turner’s syndrome: a novel association. Clin Exp Rheumatol. 1996;14(4):449–50.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Zulian F, Schumacher HR, Calore A, Goldsmith DP, Athreya BH. Juvenile arthritis in Turner’s syndrome: a multicenter study. Clin Exp Rheumatol. 1998;16(4):489–94.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Rosina P, Segalla G, Magnanini M, Chieregato C, Barba A. Turner’s syndrome associated with psoriasis and alopecia areata. J Eur Acad Dermatol Venereol. 2003;17(1):50–2.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Oiso N, Ota T, Kawara S, Kawada A. Pustular psoriasis and vitiligo in a patient with Turner syndrome. J Dermatol. 2007;34(10):727–9.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Pessach IM, Notarangelo LD. X-linked primary immunodeficiencies as a bridge to better understanding X-chromosome related autoimmunity. J Autoimmun. 2009;33(1):17–24.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Lessard CJ, Ice JA, Adrianto I, et al. The genomics of autoimmune disease in the era of genome-wide association studies and beyond. Autoimmun Rev. 2012;11(4):267–75.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Larizza D, Calcaterra V, Martinetti M. Autoimmune stigmata in Turner syndrome: when lacks an X chromosome. J Autoimmun. 2009;33(1):25–30.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Larizza D, Cuccia M, Martinetti M, et al. Adrenocorticotrophin stimulation and HLA polymorphisms suggest a high frequency of heterozygosity for steroid 21-hydroxylase deficiency in patients with Turner’s syndrome and their families. Clin Endocrinol. 1994;40(1):39–45.CrossRefGoogle Scholar
  34. 34.
    Brazzelli V, Larizza D, Martinetti M, et al. Halo nevus, rather than vitiligo, is a typical dermatologic finding of Turner’s syndrome: clinical, genetic, and immunogenetic study in 72 patients. J Am Acad Dermatol. 2004;51(3):354–8.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Larizza D, Calcaterra V, Martinetti M, et al. Helicobacter pylori infection and autoimmune thyroid disease in young patients: the disadvantage of carrying the human leukocyte antigen-DRB1∗0301 allele. J Clin Endocrinol Metab. 2006;91(1):176–9.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Larizza D, Martinetti M, Lorini R, et al. Parental segregation of autoimmunity in patients with Turner’s syndrome: preferential paternal transmission? J Autoimmun. 1999;12(1):65–72.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Jensen K, Petersen PH, Nielsen EL, Dahl G, Nielsen J. Serum immunoglobulin M, G, and A concentration levels in Turner’s syndrome compared with normal women and men. Hum Genet. 1976;31(3):329–34.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Rongen-Westerlaken C, Rijkers GT, Scholtens EJ, et al. Immunologic studies in Turner syndrome before and during treatment with growth hormone. The Dutch Growth Hormone Working Group. J Pediatr. 1991;119(2):268–72.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Lorini R, Ugazio AG, Cammareri V, et al. Immunoglobulin levels, T-cell markers, mitogen responsiveness and thymic hormone activity in Turner’s syndrome. Thymus. 1983;5(2):61–6.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Bonamico M, Pasquino AM, Mariani P, et al. Prevalence and clinical picture of celiac disease in Turner syndrome. J Clin Endocrinol Metab. 2002;87(12):5495–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Chakhtoura Z, Vigoureux S, Courtillot C, Tejedor I, Touraine P. Vulvar lichen sclerosus is very frequent in women with Turner syndrome. J Clin Endocrinol Metab. 2014;99(4):1103–4.PubMedCrossRefGoogle Scholar
  42. 42.
    Neill SM, Lewis FM, Tatnall FM, Cox NH. British association of dermatologists’ guidelines for the management of lichen sclerosus 2010. Br J Dermatol. 2010;163(4):672–82.PubMedCrossRefGoogle Scholar
  43. 43.
    Haidopoulos D, Bakolas G, Michala L. Turner syndrome: don’t forget the vulva. Endocrinol Diabetes Metab Case Rep. 2016;2016:160016.PubMedPubMedCentralGoogle Scholar
  44. 44.
    Irvine WJ, Chan MMW, Scarth L, et al. Immunological aspects of premature ovarian failure associated with idiopathic Addison’s disease. Lancet. 1968;2(7574):883–7.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Sokol L, Stueben ET, Jaikishen JP, Lamarche MB. Turner syndrome associated with acquired von Willebrand disease, primary biliary cirrhosis, and inflammatory bowel disease. Am J Hematol. 2002;70(3):257–9.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Obara-Moszynska M, Banaszak M, Niedziela M. Growth hormone therapy in a girl with Turner syndrome and diabetes type 1 – case report. Pediatr Endocrinol Diabetes Metab. 2015;20(2):75–81.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Gonc EN, Ozon A, Alikasifoglu A, Kandemir N. Type 1 diabetes mellitus in a 3 1/2 year-old girl with Turner’s syndrome. J Pediatr Endocrinol Metab. 2002;15(8):1203–6.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Hjerrild BE, Holst JJ, Juhl CB, Christiansen JS, Schmitz O, Gravholt CH. Delayed β-cell response and glucose intolerance in young women with Turner syndrome. BMC Endocr Disord. 2011;11:6.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Bakalov VK, Cooley MM, Quon MJ, et al. Impaired insulin secretion in the Turner metabolic syndrome. J Clin Endocrinol Metab. 2004;89(7):3516–20.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Højbjerg Gravholt C, Naeraa RW, Nyholm B, et al. Glucose metabolism, lipid metabolism, and cardiovascular risk factors in adult Turner’s syndrome. Diabetes Care. 1998;21(7):1062–70.CrossRefGoogle Scholar
  51. 51.
    Holl RW, Kunze D, Etzrodt H, Teller W, Heinze E. Turner syndrome: final height, glucose tolerance, bone density and psychosocial status in 25 adult patients. Eur J Pediatr. 1994;153(1):11–6.PubMedCrossRefGoogle Scholar
  52. 52.
    Polychronakos C, Letarte J, Collu R, Ducharme JR. Carbohydrate intolerance in children and adolescents with Turner syndrome. J Pediatr. 1980;96(6):1009–14.PubMedCrossRefGoogle Scholar
  53. 53.
    AvRuskin TW, Crigler JF, Soeldner JS. Turner’s syndrome and carbohydrate metabolism. I. Impaired insulin secretion after tolbutamide and glucagon stimulation tests: evidence of insulin deficiency. Am J Med Sci. 1979;277(2):145–52.PubMedCrossRefGoogle Scholar
  54. 54.
    Nielsen J, Johansen K, Yde H. The frequency of diabetes mellitus in patients with Turner’s syndrome and pure gonadal dysgenesis. Blood glucose, plasma insulin and growth hormone level during an oral glucose tolerance test. Acta Endocrinol. 1969;62(2):251–69.PubMedCrossRefGoogle Scholar
  55. 55.
    Forbes AP, Engel E. The high incidence of diabetes mellitus in 41 patients with gonadal dysgenesis, and their close relatives. Metabolism. 1963;12:428–39.PubMedGoogle Scholar
  56. 56.
    Schoemaker MJ, Swerdlow AJ, Higgins CD, Wright AF, Jacobs PA. Mortality in women with Turner syndrome in Great Britain: a national cohort study. J Clin Endocrinol Metab. 2008;93(12):4735–42.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Caprio S, Boulware S, Diamond M, et al. Insulin resistance: an early metabolic defect of Turner’s syndrome. J Clin Endocrinol Metab. 1991;72(4):832–6.PubMedCrossRefGoogle Scholar
  58. 58.
    Salgin B, Amin R, Yuen K, Williams RM, Murgatroyd P, Dunger DB. Insulin resistance is an intrinsic defect independent of fat mass in women with Turner’s syndrome. Horm Res. 2006;65(2):69–75.PubMedGoogle Scholar
  59. 59.
    Ostberg JE, Attar MJH, Mohamed-Ali V, Conway GS. Adipokine dysregulation in Turner syndrome: comparison of circulating interleukin-6 and leptin concentrations with measures of adiposity and C-reactive protein. J Clin Endocrinol Metab. 2005;90(5):2948–53.PubMedCrossRefGoogle Scholar
  60. 60.
    Gravholt CH. Epidemiological, endocrine and metabolic features in Turner syndrome. Eur J Endocrinol. 2004;151(6):657–87.PubMedCrossRefGoogle Scholar
  61. 61.
    Cicognani A, Mazzanti L, Tassinari D, et al. Differences in carbohydrate tolerance in Turner syndrome depending on age and karyotype. Eur J Pediatr. 1988;148:64–8.PubMedCrossRefGoogle Scholar
  62. 62.
    Bakalov VK, Cheng C, Zhou J, Bondy CA. X-chromosome gene dosage and the risk of diabetes in Turner syndrome. J Clin Endocrinol Metab. 2009;94(9):3289–96.PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Menzinger G, Fallucca F, Andreani D, Wais S. Klinefelter’s syndrome and diabetes mellitus. Lancet. 1966;288(7466):747–8.CrossRefGoogle Scholar
  64. 64.
    Bojesen A, Kristensen K, Birkebaek NH, et al. The metabolic syndrome is frequent in Klinefelter’s syndrome and is associated with abdominal obesity and hypogonadism. Diabetes Care. 2006;29(7):1591–8.PubMedCrossRefGoogle Scholar
  65. 65.
    Gravholt CH, Hjerrild BE, Mosekilde L, et al. Body composition is distinctly altered in Turner syndrome: relations to glucose metabolism, circulating adipokines, and endothelial adhesion molecules. Eur J Endocrinol. 2006;155(4):583–92.PubMedCrossRefGoogle Scholar
  66. 66.
    Calcaterra V, Brambilla P, Carnevale Maffe G, et al. Metabolic syndrome in Turner syndrome and relation between body composition and clinical, genetic, and ultrasonographic characteristics. Metab Syndr Relat Disord. 2014;12(3):159–64.PubMedCrossRefGoogle Scholar
  67. 67.
    Wojcik M, Janus D, Zygmunt-Gorska A, Starzyk JB. Insulin resistance in adolescents with Turner syndrome is comparable to obese peers, but the overall metabolic risk is lower due to unknown mechanism. J Endocrinol Investig. 2015;38(3):345–9.CrossRefGoogle Scholar
  68. 68.
    Elsheikh M, Bird R, Casadei B, Conway GS, Wass JA. The effect of hormone replacement therapy on cardiovascular hemodynamics in women with Turner’s syndrome. J Clin Endocrinol Metab. 2000;85(2):614–8.PubMedGoogle Scholar
  69. 69.
    Sas T, de Muinck Keizer-Schrama S, Aanstoot HJ, Stijnen T, Drop S. Carbohydrate metabolism during growth hormone treatment and after discontinuation of growth hormone treatment in girls with Turner syndrome treated with once or twice daily growth hormone injections. Clin Endocrinol. 2000;52(6):741–7.CrossRefGoogle Scholar
  70. 70.
    Radetti G, Pasquino B, Gottardi E, Boscolo Contadin I, Aimaretti G, Rigon F. Insulin sensitivity in Turner’s syndrome: influence of GH treatment. Eur J Endocrinol. 2004;151(3):351–4.PubMedCrossRefGoogle Scholar
  71. 71.
    Sas TCJ, De Muinck Keizer-Schrama SMPF, Stijnen T, Aanstoot HJ, Drop SLS. Carbohydrate metabolism during long-term growth hormone (GH) treatment and after discontinuation of GH treatment in girls with Turner syndrome participating in a randomized dose-response. J Clin Endocrinol Metab. 2000;141(2):769–75.Google Scholar
  72. 72.
    Christian T, Britta H, Kristian Havmand M, et al. Low myocardial glucose uptake in Turner syndrome is unaffected by growth hormone: a randomized, placebo-controlled FDG-PET study. Clin Endocrinol. 2015;83(1):133–40.CrossRefGoogle Scholar
  73. 73.
    Gravholt CH, Naeraa RW. Reference values for body proportions and body composition in adult women with Ullrich-Turner syndrome. Am J Med Genet. 1997;72(4):403–8.PubMedCrossRefGoogle Scholar
  74. 74.
    Bondy CA. Care of girls and women with Turner syndrome: a guideline of the Turner Syndrome Study Group. J Clin Endocrinol Metab. 2007;92(1):10–25.PubMedCrossRefGoogle Scholar
  75. 75.
    Giordano R, Forno D, Lanfranco F, Manieri C, Ghizzoni L, Ghigo E. Metabolic and cardiovascular outcomes in a group of adult patients with Turner’s syndrome under hormonal replacement therapy. Eur J Endocrinol. 2011;164(5):819–26.PubMedCrossRefGoogle Scholar
  76. 76.
    Elsheikh M, Conway GS. The impact of obesity on cardiovascular risk factors in Turner’s syndrome. Clin Endocrinol. 1998;49(4):447–50.CrossRefGoogle Scholar
  77. 77.
    Garden AS, Diver MJ, Fraser WD. Undiagnosed morbidity in adult women with Turner’s syndrome. Clin Endocrinol. 1996;45(5):589–93.CrossRefGoogle Scholar
  78. 78.
    Ross JL, Feuillan P, Long LM, Kowal K, Kushner H, Cutler GB. Lipid abnormalities in Turner syndrome. J Pediatr. 1995;126(2):242–5.PubMedCrossRefGoogle Scholar
  79. 79.
    Van PL, Bakalov VK, Bondy CA. Monosomy for the X-chromosome is associated with an atherogenic lipid profile. J Clin Endocrinol Metab. 2006;91(8):2867–70.PubMedCrossRefGoogle Scholar
  80. 80.
    Sagi L, Zuckerman-Levin N, Gawlik A, et al. Clinical significance of the parental origin of the X chromosome in Turner syndrome. J Clin Endocrinol Metab. 2007;92(3):846–52.PubMedCrossRefGoogle Scholar
  81. 81.
    Wooten N, Bakalov VK, Hill S, Bondy CA. Reduced abdominal adiposity and improved glucose tolerance in growth hormone-treated girls with Turner syndrome. J Clin Endocrinol Metab. 2008;93(6):2109–14.PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Gravholt CH, Naeraa RW, Brixen K, et al. Short-term growth hormone treatment in girls with turner syndrome decreases fat mass and insulin sensitivity: a randomized, double-blind, placebo-controlled, crossover study. Pediatrics. 2002;110(5):889–96.PubMedCrossRefGoogle Scholar
  83. 83.
    Bannink EMN, Van Der Palen RLF, Mulder PGH, De Muinck Keizer-Schrama SMPF. Long-term follow-up of GH-treated girls with turner syndrome: metabolic consequences. Horm Res. 2009;71(6):343–9.PubMedGoogle Scholar
  84. 84.
    Mortensen KH, Andersen NH, Gravholt CH. Cardiovascular phenotype in Turner syndrome—integrating cardiology, genetics, and endocrinology. Endocr Rev. 2012;33(5):677–714.PubMedCrossRefGoogle Scholar
  85. 85.
    Bakalov VK, Bondy CA. Fracture risk and bone mineral density in Turner syndrome. Rev Endocr Metab Disord. 2008;9(2):145–51.PubMedCrossRefGoogle Scholar
  86. 86.
    Gravholt CH, Vestergaard P, Hermann AP, Mosekilde L, Brixen K, Christiansen JS. Increased fracture rates in Turner’s syndrome: a nationwide questionnaire survey. Clin Endocrinol. 2003;59(1):89–96.CrossRefGoogle Scholar
  87. 87.
    Han TS, Cadge B, Conway GS. Hearing impairment and low bone mineral density increase the risk of bone fractures in women with Turner’s syndrome. Clin Endocrinol. 2006;65(5):643–7.CrossRefGoogle Scholar
  88. 88.
    Landin-Wilhelmsen K, Bryman I, Windh M, Wilhelmsen L. Osteoporosis and fractures in Turner syndrome-importance of growth promoting and oestrogen therapy. Clin Endocrinol. 1999;51(4):497–502.CrossRefGoogle Scholar
  89. 89.
    Ross JL, Long LM, Feuillan P, Cassorla F, Cutler GB. Normal bone density of the wrist and spine and increased wrist fractures in girls with Turner’s syndrome. J Clin Endocrinol Metab. 1991;73(2):355–9.PubMedCrossRefGoogle Scholar
  90. 90.
    Bakalov VK, Chen ML, Baron J, et al. Bone mineral density and fractures in turner syndrome. Am J Med. 2003;115:259–64.PubMedCrossRefPubMedCentralGoogle Scholar
  91. 91.
    Hanton L, Axelrod L, Bakalov V, Bondy CA. The importance of estrogen replacement in young women with Turner syndrome. J Womens Health (Larchmt). 2003;12(10):971–7.CrossRefGoogle Scholar
  92. 92.
    Rao E, Weiss B, Fukami M, et al. Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure in idiopathic short stature and Turner syndrome. Nat Genet. 1997;16(1):54–63.PubMedCrossRefPubMedCentralGoogle Scholar
  93. 93.
    Clement-Jones M, Schiller S, Rao E, et al. The short stature homeobox gene SHOX is involved in skeletal abnormalities in Turner syndrome. Hum Mol Genet. 2000;9(5):695–702.PubMedCrossRefPubMedCentralGoogle Scholar
  94. 94.
    Gravholt CH, Lauridsen AL, Brixen K, Mosekilde L, Heickendorff L, Christiansen JS. Marked disproportionality in bone size and mineral, and distinct abnormalities in bone markers and calcitropic hormones in adult Turner syndrome: a cross-sectional study. J Clin Endocrinol Metab. 2002;87(6):2798–808.PubMedCrossRefPubMedCentralGoogle Scholar
  95. 95.
    Bakalov VK, Van PL, Baron J, Reynolds JC, Bondy CA. Growth hormone therapy and bone mineral density in Turner syndrome. J Clin Endocrinol Metab. 2004;89(10):4886–9.PubMedCrossRefPubMedCentralGoogle Scholar
  96. 96.
    El-Mansoury M, Barrenäs M-L, Bryman I, et al. Chromosomal mosaicism mitigates stigmata and cardiovascular risk factors in Turner syndrome. Clin Endocrinol. 2007;66(5):744–51.CrossRefGoogle Scholar
  97. 97.
    Nissen N, Gravholt CH, Abrahamsen B, et al. Disproportional geometry of the proximal femur in patients with Turner syndrome: a cross-sectional study. Clin Endocrinol. 2007;67(6):897–903.CrossRefGoogle Scholar
  98. 98.
    Bakalov VK, Axelrod L, Baron J, et al. Selective reduction in cortical bone mineral density in turner syndrome independent of ovarian hormone deficiency. J Clin Endocrinol Metab. 2003;88(12):5717–22.PubMedCrossRefGoogle Scholar
  99. 99.
    Stĕpán JJ, Musilová J, Pacovský V. Bone demineralization, biochemical indices of bone remodeling, and estrogen replacement therapy in adults with Turner’s syndrome. J Bone Miner Res. 1989;4(2):193–8.PubMedCrossRefGoogle Scholar
  100. 100.
    Carrascosa A, Gussinyé M, Terradas P, Yeste D, Audí L, Vicens-Calvet E. Spontaneous, but not induced, puberty permits adequate bone mass acquisition in adolescent turner syndrome patients. J Bone Miner Res. 2000;15(10):2005–10.PubMedCrossRefPubMedCentralGoogle Scholar
  101. 101.
    Costa AMG, Lemos-Marini SHV, Baptista MTM, Morcillo AM, Maciel-Guerra AT, Guerra G. Bone mineralization in Turner syndrome: a transverse study of the determinant factors in 58 patients. J Bone Miner Metab. 2002;20(5):294–7.PubMedCrossRefPubMedCentralGoogle Scholar
  102. 102.
    Nielsen SP, Kolthoff N, Bärenholdt O, et al. Diagnosis of osteoporosis by planar bone densitometry: can body size be disregarded? Br J Radiol. 1998;71(849):934–43.CrossRefGoogle Scholar
  103. 103.
    Bertelloni S, Cinquanta L, Baroncelli GI, Simi P, Rossi S, Saggese G. Volumetric bone mineral density in young women with Turner’s syndrome treated with estrogens or estrogens plus growth hormone. Horm Res. 2000;53(2):72–6.PubMedPubMedCentralGoogle Scholar
  104. 104.
    Hansen S, Brixen K, Gravholt CH. Compromised trabecular microarchitecture and lower finite element estimates of radius and tibia bone strength in adults with turner syndrome: a cross-sectional study using high-resolution-pQCT. J Bone Miner Res. 2012;27(8):1794–803.PubMedCrossRefPubMedCentralGoogle Scholar
  105. 105.
    Holroyd CR, Davies JH, Taylor P, et al. Reduced cortical bone density with normal trabecular bone density in girls with Turner syndrome. Osteoporos Int. 2010;21(12):2093–9.PubMedCrossRefPubMedCentralGoogle Scholar
  106. 106.
    Khastgir G, Studd JWW, Fox SW, Jones J, Alaghband-zadeh J, Chow JWM. A longitudinal study of the effects of subcutaneous estrogen replacement on bone in young women with Turner’s syndrome. J Bone Miner Res. 2003;18(5):925–32.PubMedCrossRefPubMedCentralGoogle Scholar
  107. 107.
    Cleemann L, Hjerrild BE, Lauridsen AL, et al. Long-term hormone replacement therapy preserves bone mineral density in Turner syndrome. Eur J Endocrinol. 2009;161(2):251–7.PubMedCrossRefPubMedCentralGoogle Scholar
  108. 108.
    Hogler W, Briody J, Moore B, Garnett S, Lu PW, Cowell CT. Importance of estrogen on bone health in Turner syndrome: a cross-sectional and longitudinal study using dual-energy X-ray absorptiometry. J Clin Endocrinol Metab. 2004;89(1):193–9.PubMedCrossRefPubMedCentralGoogle Scholar
  109. 109.
    Saggese G, Federico G, Bertelloni S, Baroncelli GI. Mineral metabolism in Turner’s syndrome: evidence for impaired renal vitamin D metabolism and normal osteoblast function. J Clin Endocrinol Metab. 1992;75(4):998–1001.PubMedPubMedCentralGoogle Scholar
  110. 110.
    Nour MA, Burt LA, Perry RJ, Stephure DK, Hanley DA, Boyd SK. Impact of growth hormone on adult bone quality in turner syndrome: a HR-pQCT study. Calcif Tissue Int. 2016;98(1):49–59.PubMedCrossRefGoogle Scholar
  111. 111.
    Gravholt CH, Svenstrup B, Bennett P, Christiansen JS. Reduced androgen levels in adult Turner syndrome: influence of female sex steroids and growth hormone status. Clin Endocrinol. 1999;50(6):791–800.CrossRefGoogle Scholar
  112. 112.
    Apter D, Lenko HL, Perheentupa J, Söderholm A, Vihko R. Subnormal pubertal increases of serum androgens in Turner’s syndrome. Horm Res. 1982;16(3):164–73.PubMedCrossRefGoogle Scholar
  113. 113.
    Stahnke N, Keller E, Landy H, Serono Study Group. Favorable final height outcome in girls with Ullrich-Turner syndrome treated with low-dose growth hormone together with oxandrolone despite starting treatment after 10 years of age. J Pediatr Endocrinol Metab. 2002;15(2):129–38.PubMedCrossRefGoogle Scholar
  114. 114.
    Zeger MPD, Shah K, Kowal K, Cutler GB, Kushner H, Ross JL. Prospective study confirms oxandrolone-associated improvement in height in growth hormone-treated adolescent girls with Turner syndrome. Horm Res pædiatrics. 2011;75(1):38–46.CrossRefGoogle Scholar
  115. 115.
    Menke LA, Sas TCJ, Visser M, et al. The effect of the weak androgen oxandrolone on psychological and behavioral characteristics in growth hormone-treated girls with Turner syndrome. Horm Behav. 2010;57(3):297–305.PubMedCrossRefGoogle Scholar
  116. 116.
    Ross JL, Mazzocco MMM, Kushner H, Kowal K, Cutler GB, Roeltgen D. Effects of treatment with oxandrolone for 4 years on the frequency of severe arithmetic learning disability in girls with Turner syndrome. J Pediatr. 2009;155(5):714–20.PubMedCrossRefGoogle Scholar
  117. 117.
    Zuckerman-Levin N, Frolova-Bishara T, Militianu D, Levin M, Aharon-Peretz J, Hochberg Z. Androgen replacement therapy in Turner syndrome: a pilot study. J Clin Endocrinol Metab. 2009;94(12):4820–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of Endocrinology and Medical Research LaboratoriesAarhus University HospitalAarhusDenmark
  2. 2.Department of Endocrinology and Internal MedicineAarhus University HospitalAarhusDenmark
  3. 3.Department of Molecular MedicineAarhus University HospitalAarhusDenmark
  4. 4.Department of Endocrinology and Internal Medicine and Medical Research LaboratoriesAarhus University HospitalAarhusDenmark

Personalised recommendations